Correlation of pathological grade and tumor stage of urothelial carcinomas with CD109 expression

被引：40

作者：

Hagikura, Minako ^{[2
]}

Murakumo, Yoshiki ^{[1
]}

Hasegawa, Masaki ^{[5
]}

Jijiwa, Mayumi

Hagiwara, Sumitaka ^{[3
]}

Mii, Shinji

Hagikura, Shoichi ^{[2
]}

Matsukawa, Yoshihisa ^{[2
]}

Yoshino, Yasushi ^{[2
]}

Hattori, Ryohei ^{[2
]}

Wakai, Kenji ^{[4
]}

Nakamura, Shigeo ^{[6
]}

Gotoh, Momokazu ^{[2
]}

Takahashi, Masahide ^{[7
]}

机构：

[1] Nagoya Univ, Grad Sch Med, Dept Pathol, Showa Ku, Nagoya, Aichi 4668550, Japan

[2] Nagoya Univ, Grad Sch Med, Dept Urol, Nagoya, Aichi 4668550, Japan

[3] Nagoya Univ, Grad Sch Med, Dept Oral & Maxillofacial Surg, Nagoya, Aichi 4668550, Japan

[4] Nagoya Univ, Grad Sch Med, Dept Prevent Med, Nagoya, Aichi 4668550, Japan

[5] Natl Hosp Org, Dept Pathol, Nagoya Med Ctr, Nagoya, Aichi, Japan

[6] Nagoya Univ Hosp, Dept Pathol & Lab Med, Nagoya, Aichi, Japan

[7] Nagoya Univ, Grad Sch Med, Div Mol Pathol, Ctr Neurol Dis & Canc, Nagoya, Aichi 4668550, Japan

来源：

PATHOLOGY INTERNATIONAL | 2010年 / 60卷 / 11期

关键词：

CD44; CD109; immunohistochemistry; phospho-Smad2; urothelial carcinoma; TRANSITIONAL-CELL CARCINOMA; BLADDER-CANCER; TGF-BETA; E-CADHERIN; IDENTIFICATION; RECEPTORS; PROGRESSION; RECURRENCE; ACTIVATION; MUTATIONS;

D O I：

10.1111/j.1440-1827.2010.02592.x

中图分类号：

R36 [病理学];

学科分类号：

100104 ;

摘要：

Bladder cancer is one of the most common malignant diseases. Since a high-rate of recurrence is a serious problem for early stage urothelial carcinomas, new strategies for the management of recurrent urothelial carcinomas have been explored. CD109 is a glycosylphosphatidylinositol-anchored glycoprotein and is expressed in various cancer tissues, mainly squamous cell carcinomas. CD109 negatively controls transforming growth factor (TGF)-beta/Smad signaling in vitro. In this study, we analyzed the clinical significance of CD109 expression in bladder cancer using immunohistochemistry. Of 156 urothelial carcinoma tissues, 69.9% were positive for CD109, whereas CD109 was not expressed in seven normal bladder epithelia. CD109 expression was significantly higher in non-muscle-invasive (pTa+pT1) or low-grade (G1+G2) tumors than in muscle-invasive (pT2-4) or high-grade (G3) tumors, and was associated with cancer-specific survival. Simultaneous immunostaining of CD109 and phosphorylated Smad2 showed an inverse immunoreactivity relationship between the two, suggesting that CD109 inhibits TGF-beta/Smad signaling in tumor tissues. Interestingly, CD109 was found to be highly expressed in the basal layer of non-invasive urothelial carcinomas, and the expression pattern was similar to that of CD44, a marker of cancer stem cells. These findings suggest that CD109 is involved in bladder tumorigenesis and is a potential target for cancer immunotherapy.

引用

页码：735 / 743

页数：9

共 37 条

[1] Alterations of TP53 in microdissected transitional cell carcinoma of the human urinary bladder:: high frequency of TP53 accumulation in the absence of detected mutations is associated with poor prognosis [J].

Abdel-Fattah, R ;

Challen, C ;

Griffiths, TRL ;

Robinson, MC ;

Neal, DE ;

Lunec, J .

BRITISH JOURNAL OF CANCER, 1998, 77 (12) :2230-2238

[2] TGFβ:: the molecular Jekyll and Hyde of cancer [J].

Bierie, Brian ;

Moses, Harold L. .

NATURE REVIEWS CANCER, 2006, 6 (07) :506-520

[3]

BRINGUIER PP, 1993, CANCER RES, V53, P3241

[4] Cancer/testis (CT) antigens: Potential targets for immunotherapy [J].

Caballero, Otavia L. ;

Chen, Yao-Tseng .

CANCER SCIENCE, 2009, 100 (11) :2014-2021

[5]

CAIRNS P, 1991, ONCOGENE, V6, P2305

[6] Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas [J].

Cappellen, D ;

De Oliveira, C ;

Ricol, D ;

de Medina, SGD ;

Bourdin, J ;

Sastre-Garau, X ;

Chopin, D ;

Thiery, JP ;

Radvanyi, F .

NATURE GENETICS, 1999, 23 (01) :18-20

[7] Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells [J].

Chan, Keith Syson ;

Espinosa, Inigo ;

Chao, Mark ;

Wong, David ;

Ailles, Laurie ;

Diehn, Max ;

Gill, Harcharan ;

Presti, Joseph, Jr. ;

Chang, Howard Y. ;

van de Rijn, Matt ;

Shortliffe, Linda ;

Weissman, Irving L. .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2009, 106 (33) :14016-14021

[8]

del Muro XG, 2000, EUR J CANCER, V36, P357

[9] Identification of CD109 as part of the TGF-β receptor system in human keratinocytes [J].

Finnson, Kenneth W. ;

Tam, Betty Y. Y. ;

Liu, Kai ;

Marcoux, Anne ;

Lepage, Pierre ;

Roy, Stephane ;

Bizet, Albane A. ;

Philip, Anie .

FASEB JOURNAL, 2006, 20 (09) :1525-+

[10] Processing of CD109 by furin and its role in the regulation of TGF-β signaling [J].

Hagiwara, S. ;

Murakumo, Y. ;

Mii, S. ;

Shigetomi, T. ;

Yamamoto, N. ;

Furue, H. ;

Ueda, M. ;

Takahashi, M. .

ONCOGENE, 2010, 29 (15) :2181-2191

← 1 2 3 4 →